Clinical Trials
-
How Kazia’s Nuclear PD-L1 Degrader Aims to Overcome Cancer Resistance
Exploring how Kazia Therapeutics’ novel nuclear PD-L1 protein degrader, NDL2, works to overcome immunotherapy resistance in advanced solid tumors.
-
Experimental Drug Combo Doubles One-Year Survival Rates in Pancreatic Cancer Trial
A new study shows that adding an experimental drug to standard chemotherapy significantly improves survival outcomes for patients with metastatic pancreatic cancer.
-
Factor XIa Inhibitor Asundexian Cuts Recurrent Stroke Risk Without Raising Major Bleeding
FDA approval of Bayer’s asundexian shows a 26% drop in ischemic strokes while keeping major‑bleed rates comparable to placebo, offering a safer…
-
Why Oncology Trials Chase Surrogate Endpoints the FDA Ignores
An analysis of how trial designs focused on immune response metrics bypass FDA requirements, potentially delaying approvals for lifesaving cancer combinations.
-
Nangibotide Targets Acute-on-Chronic Liver Failure With Phase 2 Data Due 2027
Genfit advances TREM-1 modulator into ACLF after prior Phase 2 trials showed safety signals in septic shock and severe COVID-19.
-
FDA Approves First Antisense Drug Offering Finite Hepatitis B Therapy
Hibsago (bepirovirsen) enables a six-month treatment course that can yield a functional cure, letting some patients stop all antiviral medication.
-
START Opens First Italian Early-Phase Cancer Trial Site in Rome
Strategic partnership establishes first START site in Italy, expanding early-phase cancer trial access to patients in Rome and the Lazio region despite…
-
Blood Cancer UK launches £25m appeal to double leukaemia survival rates
Scientists aim to double leukaemia survival rates using a pioneering multi-treatment clinical trial method that previously transformed prostate cancer care.
-
KEYNOTE-B49 Shows Pembrolizumab Delays Progression in PD-L1-Positive Breast Cancer
New data from the phase 3 trial indicate that adding immunotherapy to chemotherapy improves progression-free survival in a specific subset of advanced…
-
Flawed Studies Prompt Hormone Therapy Caution for Breast Cancer Survivors
Recent reevaluations of past studies suggest hormone therapy may be safer for breast cancer survivors than previously thought, but doctors remain cautious.
-
Dendritic Cell Cancer Vaccines: One FDA Approval, Most Others Still in Trials
Only sipuleucel-T is approved for advanced prostate cancer; private clinics like Immunocine in Mexico sell personalized dendritic cell therapies still in clinical…
-
Could the Moderna-Merck Melanoma Vaccine Win FDA Approval Within Two Years? What We Know
Intismeran met primary endpoints in phase 3, but FDA filing date remains unannounced as companies race toward potential 2027 approval.
-
BMS RYZ101 Meets Phase 3 Goal in Neuroendocrine Tumors After Lutetium-177 Failure
Bristol Myers Squibb reports its actinium-225 therapy met primary endpoint in ACTION-1 trial, offering hope for a narrow group of patients.
-
GSK to Nearly Double Cancer Drugs in Trials as It Rebuilds Oncology Ahead of HIV Patent Cliff
Amidst looming patent expirations for HIV blockbusters, GSK is aggressively expanding its oncology pipeline, aiming to double late-stage cancer drug studies by…
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
Phase 1 trial of OSK gene therapy in three glaucoma patients finds no serious side effects and preliminary visual field improvements at…
-
What Clinical Trials Really Show About Tigilanol Tiglate from the Blushwood Berry
A viral social media post revived interest in the rainforest drug, but current human trials reveal targeted local results rather than a…
-
MK615 Apricot Extract: Lab Promise vs. Limited Human Trial Data
While viral clips claim MK615 kills 95% of cancer cells, a small Phase I trial showed only disease stabilization, not tumor shrinkage,…
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
A phase 1 trial of an engineered CD40 antibody published in Cancer Cell found tumor shrinkage in half of 12 patients, with…
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
The numbers first: 1,137 patients, split two to one, all with melanoma that surgeons had already removed. On Wednesday, 19 August 2026,…
-
GammaTile Trial Shows 1.3% Recurrence at One Year Versus 15.4% After Standard Radiation
HOUSTON, October 2 — GT Medical Technologies announced on September 29, 2026, that the results of the randomized, multicenter ROADS trial (NCT04365374)…
-
Dr. Joseph Sparano, TAILORx Lead Author, and the Trial That Spared Many Women Chemotherapy
NEW YORK, July 17 — A landmark clinical trial that reshaped how oncologists treat early-stage breast cancer has its roots in the…
-
Oncotype DX Evidence: What TAILORx and NCCN Ratings Show
WASHINGTON, July 17 — The strategic calculus of breast cancer treatment has shifted decisively over the past two decades, driven by a…
-
Ernexa Plans Fourth-Quarter First-in-Human Trial of ERNA-101 in Ovarian Cancer
SAN FRANCISCO, July 15 — Ernexa Therapeutics, a biotechnology company operating in the U.S. healthcare sector, is preparing to advance its lead…
-
Ernexa Moves ERNA-101 Into GMP Manufacturing Ahead of Planned IND Filing
KARACHI, July 15 — Ernexa Therapeutics is moving toward a planned first-in-human Phase 1 study for its lead cancer candidate, ERNA-101, though…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
Study Links High Sugar Intake to 28% Higher Breast Cancer Risk in Korean Women
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
Dexcom CONNECT Study Shows CGM Lowers A1C by 1.6% in Non-Insulin Type 2 Diabetes
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
-
AstraZeneca’s Imfinzi Wins FDA Approval for Bladder Cancer Patients
-
How Kazia’s Nuclear PD-L1 Degrader Aims to Overcome Cancer Resistance
-
FDA RMAT and Fast Track Designations Set New Evidence Bar for Cell Therapies
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
How the 2027 401(k) Limit Increase to $25,500 Changes Retirement Planning
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992